Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A...

Area of Science:

• Oncology
• Medical Research
• Clinical Trials

Background:

• Epidermal growth factor receptor (EGFR) pathway activation is linked to chemotherapy resistance in triple-negative breast cancer (TNBC).
• Inhibition of the EGFR pathway shows potential to sensitize TNBC cells to chemotherapy.
• EGFR overexpression is common in TNBC, making it a target for therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy of panitumumab, carboplatin, and paclitaxel as neoadjuvant therapy (NAT) in patients with doxorubicin and cyclophosphamide (AC)-resistant TNBC.
• To assess the pathological complete response (pCR)/residual cancer burden class I (RCB-I) rate in this patient population.
• To investigate the safety and tolerability of the combination regimen.

Main Methods:

• A single-arm, phase II study enrolled patients with early-stage, AC-resistant TNBC.
• Patients received panitumumab, carboplatin, and paclitaxel as the second phase of NAT.
• Whole-exome sequencing was performed on available diagnostic tumor biospecimens.

Main Results:

• The study enrolled 43 patients with AC-resistant TNBC.
• The combined pCR/RCB-I rate was 30.2%, exceeding the historical control rate of 5%.
• Common adverse events included neutropenia and anemia; no new safety signals were observed.

Conclusions:

• The combination regimen met its primary endpoint, demonstrating significant efficacy in chemotherapy-resistant TNBC.
• Panitumumab should be considered as a component of NAT for patients with chemotherapy-resistant TNBC.
• Further evaluation in larger, randomized clinical trials is recommended.